

Keith S Kaye

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8163074/publications.pdf>

Version: 2024-02-01

183
papers

7,165
citations

61945

43
h-index

62565

80
g-index

189
all docs

189
docs citations

189
times ranked

7050
citing authors

#	ARTICLE	IF	CITATIONS
1	Improving antibiotic use for sinusitis and upper respiratory tract infections: A virtual-visit antibiotic stewardship initiative. <i>Infection Control and Hospital Epidemiology</i> , 2022, 43, 1890-1893.	1.0	5
2	Third-Generation Cephalosporin-Resistant <i>Enterobacterales</i> Are Critical Priority Pathogens, Too!. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, , e0021322.	1.4	2
3	Multicenter Cohort Study of Ceftaroline Versus Daptomycin for Treatment of Methicillin-Resistant <i>Staphylococcus aureus</i> Bloodstream Infection. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab606.	0.4	12
4	Rethinking the "Pan-Culture": Clinical Impact of Respiratory Culturing in Patients With Low Pretest Probability of Ventilator-Associated Pneumonia. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	5
5	A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study). <i>Clinical Infectious Diseases</i> , 2021, 73, e4539-e4548.	2.9	114
6	Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 213-225.	4.6	255
7	Institutional quality and patient safety programs: An overview for the healthcare epidemiologist. <i>Infection Control and Hospital Epidemiology</i> , 2021, 42, 6-17.	1.0	5
8	Evaluation Strategies for Triple-Drug Combinations against Carbapenemase-Producing <i>Klebsiella Pneumoniae</i> in an <i>In Vitro</i> Hollow-Fiber Infection Model. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1074-1080.	2.3	10
9	A "resistance calculator": Simple stewardship intervention for refining empiric practices of antimicrobials in acute-care hospitals. <i>Infection Control and Hospital Epidemiology</i> , 2021, 42, 1082-1089.	1.0	2
10	Efficacy of clotrimazole for the management of oral candidiasis: A meta-analysis of randomized clinical trials. <i>Saudi Pharmaceutical Journal</i> , 2021, 29, 315-323.	1.2	5
11	Utility of radiographic keyword abstraction for identification of misdiagnosed pneumonia. <i>Infection Control and Hospital Epidemiology</i> , 2021, , 1-3.	1.0	1
12	Asymptomatic bacterisputia: Rethinking diagnostic stewardship in pneumonia. <i>Infection Control and Hospital Epidemiology</i> , 2021, 42, 737-739.	1.0	7
13	Measurement of <i>Klebsiella</i> Intestinal Colonization Density To Assess Infection Risk. <i>MSphere</i> , 2021, 6, e0050021.	1.3	18
14	Polymyxins for the treatment of lower respiratory tract infections: lessons learned from the integration of clinical pharmacokinetic studies and clinical outcomes. <i>International Journal of Antimicrobial Agents</i> , 2021, 57, 106328.	1.1	11
15	In Vitro Synergy of Colistin in Combination with Meropenem or Tigecycline against Carbapenem-Resistant <i>Acinetobacter baumannii</i> . <i>Antibiotics</i> , 2021, 10, 880.	1.5	16
16	<i>In Vitro</i> Antibacterial Activity of Cefiderocol against Multidrug-Resistant <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0264620.	1.4	29
17	Strategies for Effective Infection Prevention Programs. <i>Infectious Disease Clinics of North America</i> , 2021, 35, 531-551.	1.9	7
18	Infection Prevention and Control in Health Care, Part 1: Facility Planning and Management. <i>Infectious Disease Clinics of North America</i> , 2021, 35, xiii-xiv.	1.9	0

#	ARTICLE	IF	CITATIONS
19	Validation of N95 Filtering Facepiece Respirator Decontamination Methods Available at a Large University Hospital. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa610.	0.4	26
20	Optimizing the Management of Uncomplicated Gram-Negative Bloodstream Infections: Consensus Guidance Using a Modified Delphi Process. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab434.	0.4	31
21	The Performance of Sepsis-3 Criteria to Predict Mortality among patients with hematologic malignancy and post-transplant who have Suspected Infection. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab529.	0.4	2
22	Infection Prevention and Control in Health Care, Part II: Management of Infections. <i>Infectious Disease Clinics of North America</i> , 2021, 35, xiii-xiv.	1.9	1
23	Antimicrobial never events: Objective application of a framework to assess vancomycin appropriateness. <i>Infection Control and Hospital Epidemiology</i> , 2021, 42, 1121-1123.	1.0	1
24	Assessing the predictive performance of population pharmacokinetic models for intravenous polymyxin B in critically ill patients. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 1525-1537.	1.3	15
25	159. Improving Antibiotic Use for Sinusitis and Upper Respiratory Tract Infections: A Virtual Visit Antibiotic Stewardship Initiative. <i>Open Forum Infectious Diseases</i> , 2021, 8, S96-S96.	0.4	0
26	630. Emergence of Colistin Resistance in the OVERCOME Trial: Impact of Combination Therapy with Meropenem. <i>Open Forum Infectious Diseases</i> , 2021, 8, S418-S419.	0.4	1
27	637. Treatment Outcomes in Secondary Analysis Populations of Adult Patients the ALLIUM Phase 3 study Comparing Cefepime-Enmetazobactam to Piperacillin-Tazobactam for Complicated Urinary Tract Infections (cUTI) or Acute Pyelonephritis (AP). <i>Open Forum Infectious Diseases</i> , 2021, 8, S421-S421.	0.4	1
28	172. Inpatient Antibiotic Prescribing Patterns Using the WHO Access Watch and Reserve (AWaRe) Classification in Okinawa, Japan: A Point Prevalence Survey. <i>Open Forum Infectious Diseases</i> , 2021, 8, S195-S196.	0.4	0
29	638. The Impact of <i>in vitro</i> Synergy Between Colistin and Meropenem on Clinical Outcomes in Invasive Carbapenem-resistant Gram-negative Infections: A Report from the OVERCOME Trial. <i>Open Forum Infectious Diseases</i> , 2021, 8, S421-S422.	0.4	1
30	Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant <i>Pseudomonas aeruginosa</i> . <i>Clinical Infectious Diseases</i> , 2020, 71, 304-310.	2.9	126
31	RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections. <i>Clinical Infectious Diseases</i> , 2020, 70, 1799-1808.	2.9	254
32	Reply to Vena et al. <i>Clinical Infectious Diseases</i> , 2020, 71, 1801-1802.	2.9	2
33	Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 330-340.	4.6	88
34	Clinical Implications of Microbiologic Treatment Failure in the Setting of Clinical Cure of Bacterial Pneumonia. <i>Clinical Infectious Diseases</i> , 2020, 71, 3033-3041.	2.9	10
35	Agents of Last Resort. <i>Infectious Disease Clinics of North America</i> , 2020, 34, 723-750.	1.9	22
36	Clinical and Molecular Epidemiology of Extended-Spectrum Beta-Lactamase-Producing <i>Escherichia Coli</i> Infections in Metro Detroit: Early Dominance of the ST-131 Clone. <i>Infectious Diseases and Therapy</i> , 2020, 9, 683-690.	1.8	3

#	ARTICLE	IF	CITATIONS
37	Clinical efficacy and pharmacokinetics of colistimethate sodium and colistin in critically ill patients in an Indian hospital with high endemic rates of multidrug-resistant Gram-negative bacterial infections: A prospective observational study. <i>International Journal of Infectious Diseases</i> , 2020, 100, 497-506.	1.5	23
38	Comparison of Treatment Outcomes between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem-Cilastatin-Relebactam versus Colistin plus Imipenem-Cilastatin in Patients with Imipenem-Nonsusceptible Bacterial Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	18
39	The Impact of Multidrug-Resistant Organisms on Outcomes in Patients With Diabetic Foot Infections. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa161.	0.4	23
40	Evaluation of Renal Safety Between Imipenem/Relebactam and Colistin Plus Imipenem in Patients With Imipenem-Nonsusceptible Bacterial Infections in the Randomized, Phase 3 RESTORE-IMI 1 Study. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa054.	0.4	17
41	Humidity and Deposition Solution Play a Critical Role in Virus Inactivation by Heat Treatment of N95 Respirators. <i>MSphere</i> , 2020, 5, .	1.3	28
42	COVID-19 in older adults: clinical, psychosocial, and public health considerations. <i>JCI Insight</i> , 2020, 5, .	2.3	50
43	ColistinDose, a Mobile App for Determining Intravenous Dosage Regimens of Colistimethate in Critically Ill Adult Patients: Clinician-Centered Design and Development Study. <i>JMIR MHealth and UHealth</i> , 2020, 8, e20525.	1.8	4
44	187. Regional Distribution of Antimicrobial Resistance Among Outpatient Urine e. Coli Isolates in US Females ≥12 Years of age: a Multicenter Evaluation in 2019. <i>Open Forum Infectious Diseases</i> , 2020, 7, S222-S222.	0.4	0
45	Antibiotic Overuse at Discharge in Hospitalized Patients with Bacteriuria or Treated for Pneumonia: A Multihospital Study. <i>Infection Control and Hospital Epidemiology</i> , 2020, 41, s459-s461.	1.0	0
46	158. Intra- and Inter-hospital Epidemiology of Carbapenem-resistant klebsiella Pneumoniae in US Hospitals. <i>Open Forum Infectious Diseases</i> , 2020, 7, S208-S209.	0.4	0
47	318. Deferring Amputation in Diabetic Foot Osteomyelitis: Doing more Harm than Good?. <i>Open Forum Infectious Diseases</i> , 2020, 7, S231-S232.	0.4	0
48	836. Complete genome sequencing reveals a melting pot of diverse Klebsiella pneumoniae pathogens in two Detroit hospitals. <i>Open Forum Infectious Diseases</i> , 2020, 7, S459-S459.	0.4	0
49	679. Predominance of <i>Acinetobacter baumannii</i> Sequence Type 2 (ST2) among Clinical Isolates from Two Detroit Hospitals using Whole Genome Sequencing. <i>Open Forum Infectious Diseases</i> , 2020, 7, S392-S393.	0.4	0
50	1699. Variation of antimicrobial resistance by age groups for outpatient UTI isolates in US females: A multicenter evaluation from 2011 to 2019. <i>Open Forum Infectious Diseases</i> , 2020, 7, S832-S832.	0.4	1
51	820. Impact of pulsed xenon ultraviolet (PX-UV) light disinfection for reduction of pathogens on high touch surfaces following hospitalization. <i>Open Forum Infectious Diseases</i> , 2020, 7, S452-S453.	0.4	0
52	849. Whole Genome Sequencing Analysis of <i>Klebsiella pneumoniae</i> Isolates Reveals Diversity in Genetic Antibiotic Resistance Patterns. <i>Open Forum Infectious Diseases</i> , 2020, 7, S464-S466.	0.4	0
53	1698. Trends in antimicrobial resistance among outpatient urine E. coli isolates in US females ≥12 years of age: A multicenter evaluation from 2011 to 2019. <i>Open Forum Infectious Diseases</i> , 2020, 7, S831-S832.	0.4	0
54	1451. Genetic Analysis of Antibiotic Resistance Profiles of <i>Acinetobacter baumannii</i> Using Whole Genome Sequencing. <i>Open Forum Infectious Diseases</i> , 2020, 7, S728-S728.	0.4	0

#	ARTICLE	IF	CITATIONS
55	238. Novel Way to Evaluate Antibiotic Use Appropriateness: Moving Towards the “Never Event” Classification by Electronic Algorithm. <i>Open Forum Infectious Diseases</i> , 2020, 7, S119-S120.	0.4	0
56	Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations. <i>Clinical Infectious Diseases</i> , 2019, 68, 519-524.	2.9	118
57	Use of Colistin in Critically Ill Patients. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1145, 155-179.	0.8	8
58	Risk factors for endemic <i>Acinetobacter Baumannii</i> colonization: A case “case study. <i>American Journal of Infection Control</i> , 2019, 47, 1294-1297.	1.1	5
59	Synergistic Combination of Polymyxin B and Enrofloxacin Induced Metabolic Perturbations in Extensive Drug-Resistant <i>Pseudomonas aeruginosa</i> . <i>Frontiers in Pharmacology</i> , 2019, 10, 1146.	1.6	17
60	The devil is in the details: Factors influencing hand hygiene adherence and contamination with antibiotic-resistant organisms among healthcare providers in nursing facilities. <i>Infection Control and Hospital Epidemiology</i> , 2019, 40, 1394-1399.	1.0	11
61	2244. Clinical Outcomes with Extended Infusion (EI) vs. Intermittent Infusion (II) of Cefepime (FEP), Piperacillin/Tazobactam (TZP), and Meropenem (MEM) in Patients with Gram-Negative (GN) Bacteremia. <i>Open Forum Infectious Diseases</i> , 2019, 6, S767-S767.	0.4	0
62	Is Daptomycin plus Ceftaroline the Way To Go for Methicillin-Resistant <i>Staphylococcus aureus</i> Bacteremia?. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	0
63	Ceftaroline fosamil for the treatment of Gram-positive endocarditis: CAPTURE study experience. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 644-649.	1.1	27
64	The hypothetical impact of Accelerate Pheno [®] , [®] system on time to effective therapy and time to definitive therapy in an institution with an established antimicrobial stewardship programme currently utilizing rapid genotypic organism/resistance marker identification. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, i32-i39.	1.3	12
65	International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Antimicrobial Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). <i>Pharmacotherapy</i> , 2019, 39, 10-39.	1.2	545
66	Shifting Gears: The Future of Polymyxin Antibiotics. <i>Antibiotics</i> , 2019, 8, 42.	1.5	20
67	Open-Label Randomized Trial of Early Clinical Outcomes of Ceftaroline Fosamil Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections at Risk of Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Infectious Diseases and Therapy</i> , 2019, 8, 199-208.	1.8	7
68	Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial. <i>Clinical Infectious Diseases</i> , 2019, 69, 2045-2056.	2.9	88
69	Current Epidemiology, Etiology, and Burden of Acute Skin Infections in the United States. <i>Clinical Infectious Diseases</i> , 2019, 68, S193-S199.	2.9	103
70	Multidrug-resistant Organisms in Hospitals: What Is on Patient Hands and in Their Rooms?. <i>Clinical Infectious Diseases</i> , 2019, 69, 1837-1844.	2.9	57
71	508. Gentamicin Non-susceptibility is Associated with Persistence of Carbapenem-Resistant <i>Klebsiella pneumoniae</i> in the Urinary Tract. <i>Open Forum Infectious Diseases</i> , 2019, 6, S246-S246.	0.4	0
72	1981. Implementation of an Antifungal Stewardship Bundle Focused on Candidemia in an Indian Hospital. <i>Open Forum Infectious Diseases</i> , 2019, 6, S663-S663.	0.4	0

#	ARTICLE	IF	CITATIONS
73	1182. Clinical Outcomes of Hospital-Associated Respiratory Virus Infections. <i>Open Forum Infectious Diseases</i> , 2019, 6, S423-S424.	0.4	0
74	1542. The Evaluation of the In Vitro Synergy of Colistin in Combination with Meropenem and Tigecycline against 50 Multi-Drug-resistant <i>Acinetobacter baumannii</i> strains. <i>Open Forum Infectious Diseases</i> , 2019, 6, S562-S563.	0.4	0
75	1600. Susceptibility of $\hat{1}^2$ -Lactam-Resistant <i>Pseudomonas aeruginosa</i> to Other $\hat{1}^2$ -Lactams: Is There Truly a Lack of Cross-Resistance?. <i>Open Forum Infectious Diseases</i> , 2019, 6, S583-S584.	0.4	0
76	2000. Utilization of a "Never Event"™ Framework to Classify Antimicrobial Appropriateness. <i>Open Forum Infectious Diseases</i> , 2019, 6, S670-S671.	0.4	0
77	2222. Impact of Empiric Aminoglycoside Usage on Outcomes in Bacterial Pneumonia. <i>Open Forum Infectious Diseases</i> , 2019, 6, S758-S758.	0.4	0
78	223. Predicting Mortality Among Immunocompromised Patients Who Present With Bloodstream Infection. <i>Open Forum Infectious Diseases</i> , 2019, 6, S130-S130.	0.4	0
79	522. In Vitro Antimicrobial Activity of Ceftazidime/Avibactam Compared with Ceftolozane/Tazobactam Against Real-world Clinical Isolates of <i>Pseudomonas aeruginosa</i> at a Large Academic Tertiary Care Hospital. <i>Open Forum Infectious Diseases</i> , 2019, 6, S251-S252.	0.4	0
80	720. Efficacy of Fosfomycin for Injection (FOS) vs. Piperacillin-Tazobactam (PIP-TAZ) in Adults with Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP): ZEUS Study Outcomes in Patients With Reduced Study Drug Susceptibility. <i>Open Forum Infectious Diseases</i> , 2019, 6, S324-S324.	0.4	0
81	1035. Implementation of an Antimicrobial Stewardship Program-Led, Multifactorial Pneumonia Diagnosis and Treatment Bundle. <i>Open Forum Infectious Diseases</i> , 2019, 6, S364-S364.	0.4	0
82	1056. Evaluation of Clinical Outcomes Following Implementation of Real-Time Stewardship Team Interventions for Multi-Drug-Resistant Organisms. <i>Open Forum Infectious Diseases</i> , 2019, 6, S373-S373.	0.4	0
83	1083. Risk Factors Associated with Treatment of Asymptomatic Bacteriuria in the Emergency Department: A Multi-Hospital Cohort Study. <i>Open Forum Infectious Diseases</i> , 2019, 6, S384-S385.	0.4	0
84	521. Comparative In Vitro Activity of Meropenem/Vaborbactam and Meropenem Against a Collection of Real-World Clinical Isolates of <i>Pseudomonas aeruginosa</i> . <i>Open Forum Infectious Diseases</i> , 2019, 6, S251-S251.	0.4	2
85	The Hypothetical Impact of Accelerate Pheno on Time to Effective Therapy and Time to Definitive Therapy for Bloodstream Infections Due to Drug-Resistant Gram-Negative Bacilli. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	8
86	Implementation and Impact of an Antimicrobial Stewardship Program at a Tertiary Care Center in South India. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofy290.	0.4	28
87	Dalbavancin for the management of gram-positive osteomyelitis: Effectiveness and potential utility. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 93, 213-218.	0.8	51
88	It is time to define antimicrobial never events. <i>Infection Control and Hospital Epidemiology</i> , 2019, 40, 206-207.	1.0	9
89	Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 788.	3.8	236
90	Meropenem-vaborbactam: a new weapon in the war against infections due to resistant Gram-negative bacteria. <i>Future Microbiology</i> , 2018, 13, 971-983.	1.0	32

#	ARTICLE	IF	CITATIONS
91	Pharmacokinetics/pharmacodynamics of systemically administered polymyxin B against <i>Klebsiella pneumoniae</i> in mouse thigh and lung infection models. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 462-468.	1.3	86
92	The impact of obesity and timely antiviral administration on severe influenza outcomes among hospitalized adults. <i>Journal of Medical Virology</i> , 2018, 90, 212-218.	2.5	24
93	2075. The Hypothetical Impact of Accelerate Pheno on Time to Appropriate Therapy (TTAT) and Time to Optimal Therapy (TTOT) in an Institution with an Established Antimicrobial Stewardship Program and Rapid Genotypic Organism/Resistance Marker Identification. <i>Open Forum Infectious Diseases</i> , 2018, 5, S606-S606.	0.4	0
94	1367. Clinical Cure in Secondary Efficacy Populations in Patients With Complicated Urinary Tract Infection Treated With ZTI-01 (Fosfomycin for Injection): Findings From the ZEUS Trial. <i>Open Forum Infectious Diseases</i> , 2018, 5, S418-S419.	0.4	1
95	<i>Pseudomonas aeruginosa</i> - Difficult to Outmanoeuvre. <i>Indian Journal of Medical Microbiology</i> , 2018, 36, 301-302.	0.3	2
96	An Update on Antimicrobial Resistance and the Role of Newer Antimicrobial Agents for <i>Pseudomonas aeruginosa</i> . <i>Indian Journal of Medical Microbiology</i> , 2018, 36, 303-316.	0.3	20
97	1467. Clinical Significance of Microbiologic Treatment Failure Following Clinical Cure of Pneumonia. <i>Open Forum Infectious Diseases</i> , 2018, 5, S453-S454.	0.4	0
98	Epidemiology of Diabetic Foot Infection in the Metro-Detroit Area With a Focus on Independent Predictors for Pathogens Resistant to Recommended Empiric Antimicrobial Therapy. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy245.	0.4	17
99	Training infection prevention leaders for the present and future: United in patient safety. <i>American Journal of Infection Control</i> , 2018, 46, 1320-1321.	1.1	0
100	Training infection prevention leaders for the present and future: United in patient safety. <i>Infection Control and Hospital Epidemiology</i> , 2018, 39, 1398-1399.	1.0	1
101	Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant <i>Enterobacteriaceae</i> . <i>Infection and Drug Resistance</i> , 2018, Volume 11, 1461-1472.	1.1	67
102	Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant <i>Enterobacteriaceae</i> Infections: The TANGO II Randomized Clinical Trial. <i>Infectious Diseases and Therapy</i> , 2018, 7, 439-455.	1.8	313
103	Epidemiology of Carbapenem-Resistant <i>Enterobacteriaceae</i> at a Long-term Acute Care Hospital. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy224.	0.4	9
104	Meropenem-Vaborbactam for adults with complicated urinary tract and other invasive infections. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 865-876.	2.0	5
105	Comparison of the composition and in vitro activity of polymyxin B products. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 365-371.	1.1	5
106	Personalizing Polymyxin B Dosing Using an Adaptive Feedback Control Algorithm. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	67
107	Towards a Definition for Health Care-Associated Infection. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy116.	0.4	11
108	Ceftazidime/avibactam versus standard-of-care agents against carbapenem-resistant <i>Enterobacteriaceae</i> harbouring blaKPC in a one-compartment pharmacokinetic/pharmacodynamic model. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2405-2410.	1.3	12

#	ARTICLE	IF	CITATIONS
109	Colistin Resistance in Carbapenem-Resistant <i>Klebsiella pneumoniae</i> : Laboratory Detection and Impact on Mortality. <i>Clinical Infectious Diseases</i> , 2017, 64, ciw805.	2.9	150
110	Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae. <i>Virulence</i> , 2017, 8, 403-416.	1.8	93
111	Old antibiotics for multidrug-resistant pathogens: from in vitro activity to clinical outcomes. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 542-548.	1.1	35
112	Survey of vaccination knowledge and acceptance among adults admitted to an urban emergency department. <i>Vaccine</i> , 2017, 35, 1148-1151.	1.7	5
113	Electronically Available Comorbidities Should Be Used in Surgical Site Infection Risk Adjustment. <i>Clinical Infectious Diseases</i> , 2017, 65, 803-810.	2.9	17
114	<i>In Vitro</i> Assessment of Combined Polymyxin B and Minocycline Therapy against <i>Klebsiella pneumoniae</i> Carbapenemase (KPC)-Producing <i>K. pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	12
115	Critical Need for Clarity in Polymyxin B Dosing. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	15
116	Gram-Negative Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group. <i>Clinical Infectious Diseases</i> , 2017, 64, S30-S35.	2.9	114
117	Bathing hospitalized dependent patients with prepackaged disposable washcloths instead of traditional bath basins: A case-crossover study. <i>American Journal of Infection Control</i> , 2017, 45, 990-994.	1.1	8
118	Polymyxin-resistant, carbapenem-resistant <i>Acinetobacter baumannii</i> is eradicated by a triple combination of agents that lack individual activity. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1415-1420.	1.3	44
119	Minocycline for the Treatment of Multidrug and Extensively Drug-Resistant <i>A. baumannii</i> : A Review. <i>Infectious Diseases and Therapy</i> , 2017, 6, 199-211.	1.8	70
120	Which Comorbid Conditions Should We Be Analyzing as Risk Factors for Healthcare-Associated Infections?. <i>Infection Control and Hospital Epidemiology</i> , 2017, 38, 449-454.	1.0	6
121	Polymyxin B in combination with meropenem against carbapenemase-producing <i>Klebsiella pneumoniae</i> : pharmacodynamics and morphological changes. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 224-232.	1.1	46
122	Reply to Manian. <i>Clinical Infectious Diseases</i> , 2017, 65, 178-179.	2.9	0
123	The Effect of Adding Comorbidities to Current Centers for Disease Control and Prevention Central-Line-Associated Bloodstream Infection Risk-Adjustment Methodology. <i>Infection Control and Hospital Epidemiology</i> , 2017, 38, 1019-1024.	1.0	18
124	Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin-Tazobactam Compared to Those on Vancomycin and Cefepime. <i>Clinical Infectious Diseases</i> , 2017, 64, 116-123.	2.9	151
125	Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> : a pooled analysis of Phase 3 clinical trials. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 268-272.	1.3	103
126	The Clinical Impact of Daptomycin Non-susceptible Enterococcus Bacteremia in Hematologic Malignancy. <i>Open Forum Infectious Diseases</i> , 2017, 4, S289-S289.	0.4	0

#	ARTICLE	IF	CITATIONS
127	Infection-Related Hospital Admissions After Prostate Biopsy in United States Men. Open Forum Infectious Diseases, 2017, 4, ofw265.	0.4	19
128	Ceftaroline Fosamil for the Treatment of Intensive Care Unit Patients With Pneumonia: CAPTURE Study Experience. Open Forum Infectious Diseases, 2017, 4, S582-S583.	0.4	0
129	Safety Results from the ZEUS Study: Multi-center, Randomized, Double-Blind Phase 2/3 Study in Hospitalized Adults with Complicated Urinary Tract Infections (cUTI) Including Acute Pyelonephritis (AP) Who Received Intravenous Fosfomycin (ZTI-01). Open Forum Infectious Diseases, 2017, 4, S524-S525.	0.4	1
130	A Comparison of Molecular Typing Methods Applied to Enterobacter cloacae complex: hsp60 Sequencing, Rep-PCR, and MLST. Pathogens and Immunity, 2017, 2, 23.	1.4	7
131	The Impact of Implementing a Multifaceted Vascular Access Management (VAM) Bundled Approach to Reduce Central Line-Associated Blood Stream Infection (CLABSI): Process and Products to Reduce CLABSI Rates in Adult and Neonatal Populations. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
132	Molecular Analysis of Colistin Resistance Among Klebsiella pneumoniae Producing K pneumoniae Carbapenemase: Heterogeneity of Genetic Mechanisms. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
133	Successful Implementation of an Electronic Pneumococcal Vaccine Protocol for Better Promotion of Pneumococcal Vaccine Administration and Compliance in a Tertiary Care Facility. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
134	Hospital Readmissions in Patients With Carbapenem-Resistant Klebsiella pneumoniae. Infection Control and Hospital Epidemiology, 2016, 37, 281-288.	1.0	24
135	Agents of Last Resort. Infectious Disease Clinics of North America, 2016, 30, 391-414.	1.9	135
136	Epidemiology of Acute Kidney Injury among Patients Receiving Concomitant Vancomycin and Piperacillin-Tazobactam: Opportunities for Antimicrobial Stewardship. Antimicrobial Agents and Chemotherapy, 2016, 60, 3743-3750.	1.4	53
137	Editorial Commentary: Colistin Dosing: Does the Fun Ever Start?. Clinical Infectious Diseases, 2016, 63, 1613-1614.	2.9	4
138	Building a Successful Infection Prevention Program. Infectious Disease Clinics of North America, 2016, 30, 567-589.	1.9	7
139	Antimicrobial Stewardship for the Infection Control Practitioner. Infectious Disease Clinics of North America, 2016, 30, 771-784.	1.9	7
140	Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections. Antimicrobial Agents and Chemotherapy, 2016, 60, 5841-5848.	1.4	58
141	Are there any ways around the exposure-limiting nephrotoxicity of the polymyxins?. International Journal of Antimicrobial Agents, 2016, 48, 622-626.	1.1	24
142	Infection Prevention and Control in Healthcare, Part II: Epidemiology and Prevention of Infections. Infectious Disease Clinics of North America, 2016, 30, xiii-xiv.	1.9	11
143	Which Comorbid Conditions Should We Be Analyzing as Risk Factors for Healthcare-Associated Infections?. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
144	Clinical and Epidemiological Significance of Carbapenem Resistance in Acinetobacter baumannii Infections. Antimicrobial Agents and Chemotherapy, 2016, 60, 3127-3131.	1.4	49

#	ARTICLE	IF	CITATIONS
145	Risk Factors and Outcomes for Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Isolation, Stratified by Its Multilocus Sequence Typing: ST258 Versus Non-ST258. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofv213.	0.4	13
146	Ceftaroline fosamil as first-line versus second-line treatment for acute bacterial skin and skin structure infections (ABSSSI) or community-acquired bacterial pneumonia (CABP). <i>Journal of Chemotherapy</i> , 2016, 28, 180-186.	0.7	10
147	Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant <i>Klebsiella pneumoniae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1203-1211.	1.3	47
148	Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae. <i>Infection Control and Hospital Epidemiology</i> , 2015, 36, 981-985.	1.0	75
149	Residence in Skilled Nursing Facilities Is Associated with Tigecycline Nonsusceptibility in Carbapenem-Resistant <i>Klebsiella pneumoniae</i> . <i>Infection Control and Hospital Epidemiology</i> , 2015, 36, 942-948.	1.0	20
150	The Complex Epidemiology of Carbapenem-Resistant Enterobacter Infections: A Multicenter Descriptive Analysis. <i>Infection Control and Hospital Epidemiology</i> , 2015, 36, 1283-1291.	1.0	17
151	Simple bedside score to optimize the time and the decision to initiate appropriate therapy for carbapenem-resistant Enterobacteriaceae. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2015, 14, 31.	1.7	21
152	Nephrotoxicity Comparison of Two Commercially Available Generic Vancomycin Products. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5470-5474.	1.4	16
153	Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Practice Guidelines for Management and Care Transitions in the Emergency Department and Hospital. <i>Journal of Emergency Medicine</i> , 2015, 48, 508-519.	0.3	88
154	Strategies for the safe use of colistin. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 1237-1247.	2.0	20
155	Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv050.	0.4	315
156	Burden of <i>Clostridium difficile</i> infection on hospital readmissions and its potential impact under the Hospital Readmission Reduction Program. <i>American Journal of Infection Control</i> , 2015, 43, 314-317.	1.1	23
157	Skin and Skin Structure Infections in Older Adults. <i>Current Geriatrics Reports</i> , 2015, 4, 70-78.	1.1	0
158	Epidemiology of CTX-M-type extended-spectrum β -lactamase-producing <i>Escherichia coli</i> among older adults. <i>American Journal of Infection Control</i> , 2015, 43, 1261-1263.	1.1	1
159	Editorial Commentary: Optimal Usage of Colistin: Are We Any Closer?. <i>Clinical Infectious Diseases</i> , 2015, 61, 1778-1780.	2.9	17
160	Genomic and Transcriptomic Analyses of Colistin-Resistant Clinical Isolates of <i>Klebsiella pneumoniae</i> Reveal Multiple Pathways of Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 536-543.	1.4	185
161	Colistin: Understanding and Applying Recent Pharmacokinetic Advances. <i>Pharmacotherapy</i> , 2015, 35, 11-16.	1.2	45
162	Demonstrating the Value of Antimicrobial Stewardship Programs to Hospital Administrators. <i>Clinical Infectious Diseases</i> , 2014, 59, S146-S153.	2.9	37

#	ARTICLE	IF	CITATIONS
163	Population Structure of KPC-Producing <i>Klebsiella pneumoniae</i> Isolates from Midwestern U.S. Hospitals. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4961-4965.	1.4	78
164	Effect of Nosocomial Bloodstream Infections on Mortality, Length of Stay, and Hospital Costs in Older Adults. <i>Journal of the American Geriatrics Society</i> , 2014, 62, 306-311.	1.3	110
165	Reconsidering Isolation Precautions for Endemic Methicillin-Resistant <i>Staphylococcus aureus</i> and Vancomycin-Resistant <i>Enterococcus</i> . <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1395.	3.8	42
166	Outcomes of carbapenem-resistant Enterobacteriaceae isolation: Matched analysis. <i>American Journal of Infection Control</i> , 2014, 42, 612-620.	1.1	43
167	Consistent Global Approach on Reporting of Colistin Doses to Promote Safe and Effective Use. <i>Clinical Infectious Diseases</i> , 2014, 58, 139-141.	2.9	60
168	Carbapenem-Resistance in Gram-Negative Bacilli and Intravenous Minocycline: An Antimicrobial Stewardship Approach at the Detroit Medical Center. <i>Clinical Infectious Diseases</i> , 2014, 59, S388-S393.	2.9	46
169	Surveillance of Carbapenem-Resistant <i>Klebsiella pneumoniae</i> : Tracking Molecular Epidemiology and Outcomes through a Regional Network. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4035-4041.	1.4	132
170	Large Retrospective Evaluation of the Effectiveness and Safety of Ceftaroline Fosamil Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2541-2546.	1.4	97
171	Impact of Different Antimicrobial Therapies on Clinical and Fiscal Outcomes of Patients with Bacteremia Due to Vancomycin-Resistant Enterococci. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3968-3975.	1.4	27
172	Evaluation of the potential impact of a carbapenem de-escalation program in an academic healthcare system. <i>Journal of Infection and Public Health</i> , 2014, 7, 50-53.	1.9	5
173	Extended-spectrum β -lactamase-producing <i>Escherichia coli</i> isolation among older adults: Epidemiology and outcomes. <i>American Journal of Infection Control</i> , 2014, 42, 565-568.	1.1	3
174	The Epidemiology and Clinical Impact of Surgical Site Infections in the Older Adult. <i>Current Translational Geriatrics and Experimental Gerontology Reports</i> , 2013, 2, 159-166.	0.7	8
175	Early Use of Daptomycin Versus Vancomycin for Methicillin-Resistant <i>Staphylococcus aureus</i> Bacteremia With Vancomycin Minimum Inhibitory Concentration ≥ 1 mg/L: A Matched Cohort Study. <i>Clinical Infectious Diseases</i> , 2013, 56, 1562-1569.	2.9	163
176	Implementation of an Antimicrobial Stewardship Pathway with Daptomycin for Optimal Treatment of Methicillin-Resistant <i>Staphylococcus aureus</i> Bacteremia. <i>Pharmacotherapy</i> , 2013, 33, 3-10.	1.2	34
177	Preface. <i>Infectious Disease Clinics of North America</i> , 2011, 25, xiii.	1.9	0
178	Antibacterial Therapy and Newer Agents. <i>Medical Clinics of North America</i> , 2011, 95, xi-xii.	1.1	0
179	Investigating the impact of the definition of previous antibiotic exposure related to isolation of extended spectrum β -Lactamase-producing <i>Klebsiella pneumoniae</i> . <i>American Journal of Infection Control</i> , 2011, 39, 390-395.	1.1	19
180	Predictors of Nosocomial Bloodstream Infections in Older Adults. <i>Journal of the American Geriatrics Society</i> , 2011, 59, 622-627.	1.3	47

#	ARTICLE	IF	CITATIONS
181	Incidence of and Risk Factors for Colistin-Associated Nephrotoxicity in a Large Academic Health System. <i>Clinical Infectious Diseases</i> , 2011, 53, 879-884.	2.9	277
182	Outbreak of Colistin-Resistant, Carbapenem-Resistant <i>Klebsiella pneumoniae</i> in Metropolitan Detroit, Michigan. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 593-599.	1.4	184
183	Strategies to Address Appropriate Fluoroquinolone Use in the Hospital. <i>Hospital Pharmacy</i> , 2010, 45, 844-853.	0.4	5